These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9071916)

  • 1. A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study.
    Aravantinos G; Skarlos DV; Kosmidis P; Athanassiades A; Bafaloukos D; Giannakakis T; Karpathios S; Fountzilas G
    Eur J Cancer; 1997 Jan; 33(1):160-3. PubMed ID: 9071916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.
    du Bois A; Lück HJ; Buser K; Meerpohl HG; Sessa C; Klaassen U; Meden H; Bochtler H; Diergarten K
    Eur J Cancer; 1997 Mar; 33(3):379-84. PubMed ID: 9155520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.
    Tropé C; Hogberg T; Kaern J; Bertelsen K; Bjorkholm E; Boman K; Himmelmann A; Horvath G; Jacobsen A; Kuoppola T; Vartianen J; Lund B; Onsrud M; Puistola U; Salmi T; Scheistroen M; Sandvei R; Simonsen E; Sorbe B; Tholander B; Westberg R
    Ann Oncol; 1998 Dec; 9(12):1301-7. PubMed ID: 9932160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Mayer AR; Homesley HD
    J Clin Oncol; 1998 Feb; 16(2):405-10. PubMed ID: 9469322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer.
    Phillips KA; Friedlander M; Olver I; Evans B; Smith J; Fitzharris B; McCrystal M; Joughin J; Bishop J
    Aust N Z J Med; 1995 Aug; 25(4):337-43. PubMed ID: 8540875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Ball H; Hummel SJ; Barrett RJ
    J Clin Oncol; 1994 Sep; 12(9):1748-53. PubMed ID: 7916038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.
    Bruzzone M; Catsafados E; Miglietta L; Amoroso D; Pedulla F; Giannessi PG; Locatelli MC; D'Antona A; Foglia G; Mammoliti S; Turno F; Gentile A; Nicosia F; Luporini G; Ragni N; Boccardo F
    Oncology; 1996; 53(5):349-53. PubMed ID: 8784466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.
    Trimble EL; Adams JD; Vena D; Hawkins MJ; Friedman MA; Fisherman JS; Christian MC; Canetta R; Onetto N; Hayn R
    J Clin Oncol; 1993 Dec; 11(12):2405-10. PubMed ID: 7902426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy.
    Blom R; Palm N; Simonsen E
    Acta Oncol; 1996; 35(6):733-6. PubMed ID: 8938222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
    Rivera E; Holmes FA; Frye D; Valero V; Theriault RL; Booser D; Walters R; Buzdar AU; Dhingra K; Fraschini G; Hortobagyi GN
    Cancer; 2000 Dec; 89(11):2195-201. PubMed ID: 11147589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study.
    Pectasides D; Papadopoulou M; Varthalitis J; Mylonakis A; Kostopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(3):228-34. PubMed ID: 9560055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.